Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Weekly Jamaica.
Press releases published on November 3, 2025
Actimed Therapeutics Further Expands Intellectual Property Portfolio for Lead Compound with New Composition of Matter Patent in Japan
Patent expands IP protection for S-pindolol benzoate (ACM-001.1), reinforcing the global IP position of Actimed with granted patents in all key markets London, UK – 3 November 2025. Actimed Therapeutics Ltd (“Actimed” or “the Company”), a UK-based clinical …
VIVOLTA expands regenerative implant manufacturing capability with dedicated facility
VIVOLTA expands regenerative implant manufacturing capability with dedicated facility New High Tech Campus Eindhoven site to enable electrospun medical implant production at scale Growth Momentum: Reflecting VIVOLTA’s sustained commercial growth and the …
Avance Clinical Showcases Early Phase Expertise and the Australian Advantage for EU Biotechs at BIO-Europe Vienna
ADELAIDE, Australia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, the largest premium full-service Australian headquartered CRO with more than 30 years of early phase expertise, is highlighting its Early Phase Center of Excellence for Biotechs and …
Avance Clinical präsentiert auf der BIO-Europe in Wien seine Expertise in der Frühphase und den „Australian Advantage“ für europäische Biotechnologie-Unternehmen
ADELAIDE, Australien, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, das größte australische Full-Service-Forschungsunternehmen mit mehr als 30 Jahren Erfahrung in der Frühphasenforschung, stellt auf der BIO-Europe in Wien vom 03. bis 05. November 2025 …
AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
LONDON and MILAN, Nov. 03, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced the successful closing of a $141 million (€122 million) …
Eder Therapeutics and XCubeBio Partner to Establish Joint NewCo for Global Development and Future Market Entry Activities
SAGUENAY, Quebec and ZUG, Switzerland, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Eder Therapeutics, a Canadian biopharmaceutical company focused on rare genetic disorders and XCubeBio AG, a biotechnology platform company focused on accelerating successful …
BOOST Pharma Adds Sound Bioventures to Investor Syndicate with SEK 34 Million Investment to Advance Stem Cell Therapy for Osteogenesis Imperfecta
COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- BOOST Pharma ApS, a clinical-stage biopharmaceutical company focused on developing novel cell therapies for rare skeletal pediatric diseases, today announced that Sound Bioventures has joined its …
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing tumor-associated antigens MSLN and EpCAM Induced …
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein …
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action — — Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibitor payload, demonstrating promising preclinical efficacy …
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and …